Japan’s MHLW approves risovalisib (Risovalisib Mesilate Hydrate or Heitzexin) after chemo for ovarian clear cell carcinoma with advanced PIK3CA gene mutations
This approval is based on efficacy and safety data obtained from a single-arm, open-label, multicenter, international Phase II trial (CYH33-G201 trial). In the CYH33-G201 trial, lisovalisib 40 mg was administered orally once daily on an empty stomach to patients with PIK3CA gene mutation-positive ovarian clear cell cancer who had received prior chemotherapy. The primary endpoint, the objective response rate (ORR) based on independent imaging assessment was 34.5% (95% confidence interval: 24.28 – 45.69) in the 84 patients evaluated for efficacy.
Share:
More News
“The designation reinforces the significant unmet need for effective treatment options for patients with advanced breast cancer,” said Charles Baum, M.D., Ph.D., Chief Executive Officer of Terremoto Biosciences. “We are committed to advancing highly selective therapies designed to expand treatment options for patients with difficult to treat cancers.”
“Up to five U.S. clinical sites are planned for THIO-101 Parts C and D this year, and we expect to activate a second U.S. site in the coming weeks,” said Vlad Vitoc, M.D., Founder and Chief Executive Officer of MAIA. “To date, data has shown overall survival (OS) beyond two
Dr. Jason Zhu, Executive Director and Chief Executive Officer of Henlius, said: “The positive CHMP opinion for the sqNSCLC indication marks another important milestone in serplulimab’s regulatory journey in Europe and brings the product one step closer to achieving comprehensive coverage of first-line lung cancer treatment indications in the EU.